Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Futibatinib: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 18, pp. 1737-1743
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 21
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
The role of the methoxy group in approved drugs
Debora Chiodi, Yoshihiro Ishihara
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116364-116364
Closed Access | Times Cited: 16
The significance of chirality in contemporary drug discovery-a mini review
Narmatha Senkuttuvan, Boopathi Komarasamy, Rajavenkatesh Krishnamoorthy, et al.
RSC Advances (2024) Vol. 14, Iss. 45, pp. 33429-33448
Open Access | Times Cited: 13
Synthetic Approaches to the New Drugs Approved During 2022
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4376-4418
Closed Access | Times Cited: 9
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Emerging Therapies in Management of Cholangiocarcinoma
Jessica Speckart, Veronica Rasmusen, Zohray Talib, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 613-613
Open Access | Times Cited: 7
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Giovanni Brandi, Valeria Relli, Marzia Deserti, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Rameshwar S. Cheke, Prashant S. Kharkar
Drug Development Research (2023) Vol. 85, Iss. 1
Open Access | Times Cited: 12
Adopted green spectrophotometric determination of futibatinib based on diazo coupling with 1-naphthol and assisted computational calculations
Reem M. Alnemari, Saleh l. Alaqel, Atiah H. Almalki, et al.
Journal of Photochemistry and Photobiology A Chemistry (2025), pp. 116396-116396
Closed Access
Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)
Angelo Pirozzi, Celine Hoyek, Naohiro Okano, et al.
Expert Opinion on Drug Safety (2025), pp. 1-8
Closed Access
Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer
Shuting Jia, Yuye Jia, Sufang Liang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117827-117827
Closed Access | Times Cited: 3
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer
Mei Peng, Jun Deng, Xiangping Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Discovery of BW710 as a Potent, Selective and Orally Bioavailable Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitor
Bowen Yang, Qiuju Xun, Yuan Tian, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117339-117339
Closed Access
Covalent inhibitors possessing autophagy-modulating capabilities: charting novel avenues in drug design and discovery
Yutong Wang, Shiyu Luo, Hongbao Sun, et al.
Drug Discovery Today (2025), pp. 104347-104347
Closed Access
Synthesis and clinical application of new drugs approved by FDA in 2022
Jingyi Zhang, Yatao Wang, Lu Sun, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
Parveen Kumar Goyal, Kavita Sangwan
Current Pharmacology Reports (2024) Vol. 10, Iss. 2, pp. 96-120
Closed Access | Times Cited: 3
Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications
T. N. Rekha, Arifullah Mohammed
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116441-116441
Closed Access | Times Cited: 3
Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors
Chunpu Li, Yang Dai, Xiangtai Kong, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3226-3249
Closed Access | Times Cited: 7
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review
Kavita Sangwan, Vipasha Sharma, Parveen Kumar Goyal
Current Molecular Medicine (2023) Vol. 24, Iss. 6, pp. 734-750
Closed Access | Times Cited: 7
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
Satoshi Kawano, Megumi Ikemori Kawada, Sayo Fukushima, et al.
Anticancer Research (2024) Vol. 44, Iss. 6, pp. 2393-2406
Open Access | Times Cited: 2
Modular and Diverse Synthesis of Acrylamides by Palladium‐Catalyzed Hydroaminocarbonylation of Acetylene
Matthias Beller, Zhusong Cao, Qiang Wang, et al.
Angewandte Chemie International Edition (2024)
Open Access | Times Cited: 2
Modular and Diverse Synthesis of Acrylamides by Palladium‐Catalyzed Hydroaminocarbonylation of Acetylene
Matthias Beller, Zhusong Cao, Qiang Wang, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 40
Open Access | Times Cited: 2
A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors
Anuradha Mehra, Rekha Sangwan
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 25, Iss. 1, pp. 2-23
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top